Regenxbio
RGNX
182 hedge funds and large institutions have $778M invested in Regenxbio in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 26 closing their positions.
21% more call options, than puts
Call options by funds: $1.84M | Put options by funds: $1.53M
1.27% more ownership
Funds ownership: 81.12% → 82.39% (+1.3%)
3% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 63
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
1% less funds holding
Funds holding: 183 → 182 (-1)
16% less capital invested
Capital invested by funds: $927M → $778M (-$149M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$4.24M |
| 4 |
BlackRock
New York
|
+$3.05M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
-$6.07M |
| 2 |
JP Morgan Chase
New York
|
-$5.88M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$5.66M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$2.91M |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$1.99M |
RGNX Hedge Fund Activity: Q4 2022 in Review
182 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q4 2022, worth a combined $778M — down 16% from $927M a quarter earlier.
Fund positioning in RGNX was balanced in Q4 2022: 26 funds opened new positions, 26 closed out, 65 added to existing stakes and 63 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.7M. The largest seller was First Manhattan, cutting an estimated $6.07M.
- 182 institutional investors held Regenxbio (RGNX) as of Q4 2022, down from 183 in Q3 2022.
- Funds reported $778M of Regenxbio stock for Q4 2022, down 16% quarter-over-quarter.
- 26 funds opened new Regenxbio positions in Q4 2022 and 26 closed out, a net change of 0 holders.
- The largest Regenxbio buyer in Q4 2022 was Citadel Advisors, an estimated $12.7M added.
- The largest Regenxbio seller in Q4 2022 was First Manhattan, an estimated $6.07M sold.
Based on aggregated 13F filings for Q4 2022.